SU212 是一种鬼臼毒素衍生的 ENO1 抑制剂和 AMPK 激活剂,能选择性诱导细胞氧化磷酸化、降低肿瘤细胞的糖酵解活性和葡萄糖摄取,并直接结合 ENO1 而不影响正常细胞中的通路;它可诱导凋亡,并通过蛋白酶体和自噬途径诱导 ENO1 降解但不抑制其催化活性,同时通过激活 AMPK(不依赖于能量应激,也不受血糖或胰岛素状态影响)导致三阴乳腺癌细胞发生 M 期阻滞和凋亡,在体外表现出强效抗肿瘤活性,并在同系、异种移植和糖尿病小鼠模型中抑制肿瘤生长和转移,具有优异的安全性特征,可用于 TNBC、糖尿病和脂肪肝研究。
产品编号: MS-B36226 CAS No.: 1262219-89-5 分子式: C25H27NO6 分子量: 437.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

SU212 是一种鬼臼毒素衍生的 ENO1 抑制剂和 AMPK 激活剂,能选择性诱导细胞氧化磷酸化、降低肿瘤细胞的糖酵解活性和葡萄糖摄取,并直接结合 ENO1 而不影响正常细胞中的通路;它可诱导凋亡,并通过蛋白酶体和自噬途径诱导 ENO1 降解但不抑制其催化活性,同时通过激活 AMPK(不依赖于能量应激,也不受血糖或胰岛素状态影响)导致三阴乳腺癌细胞发生 M 期阻滞和凋亡,在体外表现出强效抗肿瘤活性,并在同系、异种移植和糖尿病小鼠模型中抑制肿瘤生长和转移,具有优异的安全性特征,可用于 TNBC、糖尿病和脂肪肝研究。

生物实验数据

生物活性 SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator that selectively induces cellular oxidative phosphorylation, reduces glycolytic activity and glucose uptake in tumor cells, and directly binds ENO1 without affecting pathways in normal cells; it induces apoptosis and promotes ENO1 degradation through proteasomal and autophagic pathways without inhibiting its catalytic activity, and by activating AMPK (independent of energy stress and unaffected by blood glucose or insulin status) it causes M phase arrest and apoptosis in triple-negative breast cancer cells, exhibiting potent antitumor activity in vitro, inhibiting tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models with an excellent safety profile, and is applicable for research on TNBC, diabetes, and fatty liver disease.
体外研究
(In Vitro)

SU212 (0.01-850 μM, 48 小时) 对三阴性乳腺癌细胞 (MDA-MB-231) 表现出比 Etoposide 更低的毒性和更高的效力,其 IC50 为 0.26 μM;其在人源 TNBC 细胞中的 IC50 值分别为:MDA-MB-468 0.1 μM、SUM159 0.24 μM、BT549 0.037 μM;在小鼠 TNBC 细胞系中的 IC50 值分别为:4T1 0.85 μM、EMT6 0.18 μM、E0771 0.039 μM、PY8119 0.31 μM。
SU212 (0.5 μM, 6 小时) 在 MDA-MB-231 细胞中的作用靶点与 Etoposide 不同,并通过蛋白酶体和自噬途径促进 ENO1 降解,此作用可被 MG132 或3 MA 共处理部分阻断。
SU212 (0.1-10 μM, 3 分钟-6 小时) 能提高 ENO1 和 ENO3 的热稳定性,且与 ENO1 的相互作用更强,并在多种 TNBC 细胞系 (MDA-MB-231, MDA-MB-468 和 EMT6) 中表现出剂量依赖性效应。
SU212 (0.25 或 0.5 μM, 1.5 小时) 抑制了 MDA-MB-231、MCF12A 和 HEK293 细胞的总体氧消耗率、细胞外酸化率及糖酵解率但不影响正常细胞的糖酵解率和活力。
SU212 (0.1-0.5 μM, 6-10 天) 可抑制 TNBC 细胞的肿瘤再生和复发。
SU212 (0.1-0.5 μM,6 或 12 小时) 在 MDA-MB-468 和 MDA-MB-231 细胞中诱导 G2/M 期阻滞。
SU212 (0.5 μM,12 小时) 降低正常乳腺细胞 MCF10A、MCF12A 或 TNBC 细胞 MDA-MB-231 和 MDA-MB-468 中不同形式微管蛋白的丰度。
SU212 (0.25 或 0.5 μM,12-48 小时) 在 MDA-MB-468 和 MDA-MB-231 细胞中诱导 12-60% 的凋亡性细胞死亡而非自噬性细胞死亡。
SU212 (0.25 或 0.5 μM, 1-6 小时) 在 MDA-MB-231 细胞中通过磷酸化 AMPKα 的 Thr172 位点激活 AMPK,并在 MDA-MB-468 和 MDA-MB-231 细胞中诱导 AMPKα 的显著激活。
SU212 (0.25 μM-0.5 μM,30 分钟至 6 小时) 抑制 MDA-MB-468 和 MDA-MB-231 细胞的乳酸生成且不影响 MDA-MB-231 细胞中 D-葡萄糖、葡萄糖-6-磷酸/果糖-6-磷酸、ATP、柠檬酸、耗氧率 (OCR)、细胞外酸化率 (ECAR) 以及 α-酮戊二酸的细胞水平。
SU212 (0.25 或 0.5 μM,6 小时) 使 MDA-MB-468 和 MDA-MB-231 细胞的细胞脂质含量降低 24-70%。
SU212 (0.5 μM,12 小时) 显著增加 MDA-MB-231 和 MDA-MB-468 细胞系中与氧化磷酸化相关的蛋白质水平,并降低与糖酵解及磷酸戊糖途径相关的蛋白质水平,但在正常乳腺细胞系中无此效应。
SU212 (0.1-0.5 μM,6 或 72 小时) 在 MDA-MB-468 和 MDA-MB-231 细胞中具有依赖 AMPK 激活的细胞毒性效应。
SU212 (0.2-0.6 μM,48 小时) 不依赖于能量应激激活 TNBC 细胞系中的 AMPK。

Western Blot Analysis

Cell Line: MDA-MB-231 and EMT6
Concentration: 0.1 μM
Incubation Time: 6 h
Result: Significantly altered the subcellular localization of eno1, most substantially limiting the membrane-bound pool, while exerting more limited effects on its nuclear and mitochondrial pools.
Induced inhibition of eno1 localization to the cell membrane was partially reversed by co-treatment with MG132 and 3MA.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0.5 μM
Incubation Time: 6 h
Result: Did not stabilizes TOP2A.
Induced ENO1 degradation, and this effect was partially rescued by co-treatment with either MG132 or 3MA.

Western Blot Analysis

Cell Line: MDA MB-231, MDA-MB-468, and EMT6
Concentration: 6 h
Incubation Time: 6 or 12 h
Result: Strongly inhibited ENO1 protein expression, does not change ENO3 protein expression.

Cell Proliferation Assay

Cell Line: MDA-MB-231, MDA-MB-468, SUM159 and BT549, 4T1, EMT6, E0771 and PY8119
Concentration: 0.1, 0.25 and 0.5 μM
Incubation Time: 6-10 days
Result: Significantly inhibited TNBC cells’ clono genic potential and eight other cancer types.

Cell Cycle Analysis

Cell Line: MDA-MB-468 and MDA-MB-231
Concentration: 0.1, 0.25 and 0.5 μM
Incubation Time: 6 or 12 h
Result: Increased the sub-g1 phase (20-35%) with 6 h.
Induced mitotic phase arrest (20-31%) with 6 h.

Western Blot Analysis

Cell Line: MDA-MB-468 and MDA-MB-231
Concentration: 0.5 μM
Incubation Time: 6 h
Result: Resulted in the downregulation of cyclin B1 and CDK1 expression, and an increase in the expression of phospho-histone H3.

Western Blot Analysis

Cell Line: MDA-MB-468 and MDA-MB-231
Concentration: 0.5 μM
Incubation Time: 12 h
Result: Cleaved PARP, Bax, Bcl-2 and CC.
Induced pro-apoptotic Bax expression and inhibited Bcl-2 expres sion, leading to a significant increase in Bax/Bcl-2 ratio.
Induced the cleavage of PARP and caspase 3.
Inhibited Beclin-1 but did not affect LC3 A/B.

Western Blot Analysis

Cell Line: MDA-MB-468, MDA-MB-231
Concentration: 0.5 μM
Incubation Time: 6 h
Result: Downregulated of mtor and acetyl-coa carboxylase (ACC) inhibition.

Western Blot Analysis

Cell Line: Dorsomorphin (MS-O41512) pretreated MDA-MB-468 and MDA-MB-231.
Concentration: 0.5 μM
Incubation Time: 6 h
Result: Did not induce AMPK Were healthier and had a morphology similar.

Cell Viability Assay

Cell Line: Dorsomorphin pretreated MDA-MB-468 and MDA-MB-231
Concentration: 0.5 μM
Incubation Time: 72 h
Result: Reverted cytotoxic effect by Dorsomorphin from 73% to 86%.

Cell Viability Assay

Cell Line: MDA-MB-468
Concentration: 0.2, 0.4 and 0.6μM
Incubation Time: 48 h
Result: Produced an additive inhibitory effect in hypoglycaemic conditions, resulting in about 20–30% enhanced inhibition (P < 0.05) relative to hyperglycaemic conditions.
Did not affect the cytotoxicity of MDA-MB-468 cells by insulin.
Maintained consistent cytotoxicity across physiological and high insulin levels (1–100 ng/ml) but modestly reduced (by 17%) at a supra-pharmacological concentration (10,000 ng/ml).
体内研究
(In Vivo)

SU212 (30 mg/kg,腹腔注射,每日一次,连续 3 天) 在 MDA-MB-231 细胞诱导的雌性 NSG 小鼠模型中,降低了细胞糖酵解速率,从而减少了肿瘤细胞的整体葡萄糖需求。
SU212 (100-400 mg/kg,腹腔注射,单次给药) 在雌性 C57BL/6 小鼠和 SD 大鼠中表现出良好的耐受性。
SU212 (30 mg/kg,腹腔注射,每周 5 天,持续 21 天或 24 天) 在同系原位 TNBC 模型中未诱发肝或肾毒性。
SU212 (20 mg/kg,腹腔注射,每周 5 天) 在杂合 MMTV-PyMT 转基因雌性小鼠模型中对肿瘤的发生和发展具有积极作用。
SU212 (30 mg/kg,腹腔注射,每周 5 天,持续 21 天) 在 TNBC 的原位 EMT6 小鼠模型中,通过诱导ENO1降解导致其亚细胞定位改变并削弱了其兼职功能。
SU212 (10 mg/kg,腹腔注射,每周 5 天,持续 32 天) 在高血糖和高胰岛素血症条件下能抑制肿瘤生长,并可能有助于改善 Leprdb (Db/Db) 小鼠模型的糖尿病和脂肪肝状况。
SU212 (15 或 30 mg/kg,腹腔注射,21 天) 在荧光素酶标记的 MDA-MB-231 异种移植小鼠模型中抑制肿瘤进展。
SU212 (30 mg/kg,腹腔注射,30 天) 在尾静脉肺转移小鼠模型中抑制肺转移。
SU212 (30 mg/kg,腹腔注射,21 天) 在 4T1 同系移植小鼠模型中通过激活 AMPK 通路展现出强效的抗肿瘤生长和抗转移活性,且无显著体重减轻或肝肾毒性并能改善脂质代谢。

Animal Model: MDA-MB-231 cells induced- female NSG mice (8-9 weeks)
Dosage: 30 mg/kg
Administration: i.p., once daily for 3 days
Result: Did not significantly reduce tumor size compared to the control.
Significantly reduced fdg uptake by tumor cells.
Animal Model: Female C57BL/6 mice and SD rats
Dosage: 100, 200, and 400 mg/kg
Administration: i.p., once
Result: Observed no signs of stress (behavioral, neurological, and auto nomic stresses.
Did not observe any significant weight loss or mortality.
Animal Model: EMT6 cells (1x105) induced-Balb/c mice and PY8119 induced-C57BL/6mice
Dosage: 30 mg/kg
Administration: i.p. 5 days a week for 21 days (EMT6 induced-Balb/c mice) or 24 days (PY8119 induced-C57BL/6mice)
Result: Significantly delayed tumor growth in both TNBC models, resulting in significantly lower tumor weight at experiment end.
Did not caused any significant changes in these markers of liver or nephrotoxicity in C57BL/6 mice bearing PY8119 tumors.
Animal Model: EMT6 cells (1x105) induced-female NSG mice
Dosage: 30 mg/kg
Administration: i.p., 5 days/week for 21 days
Result: Reduced 66% lung metastasis.
Animal Model: Female FVB/N-Tg (MMTV-PyVT) 634 Mul/Jmice (5-6 weeks)
Dosage: 20 mg/kg
Administration: i.p., five days a week
Result: Improved overall survival and reduced tumor burden and incidence.
Animal Model: PY8119 cells (1x105)induced-female Db/Db mice(10 weeks old)
Dosage: 10 mg/kg
Administration: i.p., 5 days/week for 32 days
Result: Reduced tumor growth.
Reduced overall tumor burden.
Inhibits eno1 expression.
Did not significantly affect overall mouse body weight.
Did cause a significant drop in blood glucose level.
Significantly reduces the level of AST, ALT, alkaline phosphatase and glutamate dehydroge nase (GLDH).
Significantly reduced liver weight.
Reduced fat-associated space by 80%-90%.
Resulted in a distinct mrna profile, characterized by the downregulation of pi3k pathway genes and the upregulation of mitochondrial respiration pathway genes.
Animal Model: MDA-MB-231 cells (2× 106) induced-female NOD/SCID mice (7-8 weeks)
Dosage: 15 and 30 mg/kg
Administration: i.p., 21 days
Result: Inhibited TNBC tumour growth by 46 and 71%, respectively.
Did not show significant body-weight changes and no stress or pain behaviour.
Had 42 and 81% less tumour weight at 15mg/kg and 30mg/kg doses respectively.
Animal Model: MDA-MB-231 cells (1× 106) induced-female NOD/SCID mice (6-7 weeks)
Dosage: 30 mg/kg
Administration: i.p., every day for 4 weeks
Result: Reduced the number of metastatic foci in the lung by 69%.
Animal Model: 4T1 cells (5×105) induced-female Balb/c mice (7-8 weeks)
Dosage: 30 mg/kg
Administration: i.p., 30 days
Result: Inhibited tumour growth by 40% without significant body-weight loss.
Reduced tumour weight by 46%.
Reduced the number of metastatic foci in the lung.
Inhibited the expression of Ki-67 and LDHA Bax and c-Caspase 3.
Causes an inhibition of tumour progression via the AMPK pathway.
Induced the expression of Bax and cleaved caspase 3, consistent with western blot and apoptosis assays.
Did not affect blood glucose, cholesterol, creatinine and BUN, whereas levels of triglycerides and ALP decreased signifi cantly.
Reduced tumour weight by 46%..
性状 固体
颜色 Off-white to gray

化学信息

分子量 437.48
分子式 C25H27NO6
CAS No. 1262219-89-5

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (114.29 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2858 mL11.4291 mL22.8582 mL57.1455 mL
5 mM0.4572 mL2.2858 mL4.5716 mL11.4291 mL
10 mM0.2286 mL1.1429 mL2.2858 mL5.7145 mL
15 mM0.1524 mL0.7619 mL1.5239 mL3.8097 mL
20 mM0.1143 mL0.5715 mL1.1429 mL2.8573 mL
25 mM0.0914 mL0.4572 mL0.9143 mL2.2858 mL
30 mM0.0762 mL0.3810 mL0.7619 mL1.9048 mL
40 mM0.0571 mL0.2857 mL0.5715 mL1.4286 mL
50 mM0.0457 mL0.2286 mL0.4572 mL1.1429 mL
60 mM0.0381 mL0.1905 mL0.3810 mL0.9524 mL
80 mM0.0286 mL0.1429 mL0.2857 mL0.7143 mL
100 mM0.0229 mL0.1143 mL0.2286 mL0.5715 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础